- Report
- July 2025
- 265 Pages
Global
From €5159EUR$5,850USD£4,450GBP
- Report
- April 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,416GBP
- Report
- March 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,416GBP
- Report
- February 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,416GBP
- Report
- March 2024
- 123 Pages
Middle East, Africa
From €1323EUR$1,500USD£1,141GBP
- Book
- December 2020
- 400 Pages
From €146EUR$165USD£126GBP
- Book
- May 2023
- 416 Pages
- Book
- March 2015
- 512 Pages
- Book
- February 2011
- 488 Pages

Dyslipidemia is a condition in which there is an abnormal amount of lipids (fats) in the blood. It is a major risk factor for cardiovascular disease, and is one of the most common conditions managed by cardiologists. Dyslipidemia is typically treated with lifestyle modifications, such as diet and exercise, as well as medications. Statins are the most commonly prescribed medications for dyslipidemia, and are used to reduce the levels of low-density lipoprotein (LDL) cholesterol in the blood. Other medications, such as fibrates, bile acid sequestrants, and niacin, may also be used to treat dyslipidemia.
Several companies are involved in the dyslipidemia market, including Pfizer, Merck, AstraZeneca, Sanofi, and Novartis. These companies produce a variety of medications used to treat dyslipidemia, including statins, fibrates, and bile acid sequestrants. Additionally, there are several companies that specialize in developing and marketing dietary supplements for dyslipidemia, such as Omega-3 fatty acids and plant sterols. Show Less Read more